HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

TMT-Based Quantitative Proteomic Analysis Reveals Downregulation of ITGAL and Syk by the Effects of Cycloastragenol in OVA-Induced Asthmatic Mice.

AbstractBackground:
Cycloastragenol (CAG) has been reported to alleviate airway inflammation in ovalbumin- (OVA-) induced asthmatic mice. However, its specific mechanisms remain unclear.
Objective:
This study is aimed at investigating the effects of CAG on asthma, comparing its efficacy with dexamethasone (DEX), and elucidating the mechanism of CAG's regulation.
Methods:
The asthma mouse model was induced by OVA. CAG at the optimal dose of 125 mg/kg was given every day from day 0 for 20-day prevention or from day 14 for a 7-day treatment. We observed the preventive and therapeutic effects of CAG in asthmatic mice by evaluating the airway inflammation, AHR, and mucus secretion. Lung proteins were used for TMT-based quantitative proteomic analysis to enunciate its regulatory mechanisms.
Results:
The early administration of 125 mg/kg CAG before asthma happened prevented asthmatic mice from AHR, airway inflammation, and mucus hypersecretion, returning to nearly the original baseline. Alternatively, the administration of CAG during asthma also had the same therapeutic effects as DEX. The proteomic analysis revealed that the therapeutical effects of CAG were associated with 248 differentially expressed proteins and 3 enriched KEGG pathways. We then focused on 3 differentially expressed proteins (ITGAL, Syk, and Vav1) and demonstrated that CAG treatment downregulated ITGAL, Syk, and Vav1 by quantitative real-time PCR, western blot analysis, and immunohistochemical staining.
Conclusion:
These findings suggest that CAG exerts preventive and protective effects on asthma by inhibiting ITGAL, Syk, and the downstream target Vav1.
AuthorsXueyi Zhu, Baojun Liu, Zhenhui Ruan, Mengmeng Chen, Congcong Li, Hanlin Shi, Xi Huang, Hang Yu, Yaolong Zhou, Hehua Zhu, Jing Sun, Ying Wei, Weifang Xu, Jingcheng Dong
JournalOxidative medicine and cellular longevity (Oxid Med Cell Longev) Vol. 2022 Pg. 6842530 ( 2022) ISSN: 1942-0994 [Electronic] United States
PMID36329800 (Publication Type: Journal Article)
CopyrightCopyright © 2022 Xueyi Zhu et al.
Chemical References
  • Ovalbumin
  • cycloastragenol
  • Cytokines
Topics
  • Mice
  • Animals
  • Ovalbumin (pharmacology)
  • Down-Regulation
  • Mice, Inbred BALB C
  • Proteomics
  • Bronchoalveolar Lavage Fluid
  • Asthma (chemically induced, drug therapy, metabolism)
  • Lung (metabolism)
  • Inflammation (metabolism)
  • Disease Models, Animal
  • Cytokines (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: